Fig. 1From: Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS studyFOCUS study design. PBO, placebo; EM, episodic migraine; CM, chronic migraine; V, visit; DB, double-blind; OLE, open-label extensionBack to article page